AGL 40.10 Increased By ▲ 0.10 (0.25%)
AIRLINK 131.36 Increased By ▲ 1.83 (1.41%)
BOP 6.85 Increased By ▲ 0.17 (2.54%)
CNERGY 4.62 Decreased By ▼ -0.01 (-0.22%)
DCL 9.05 Increased By ▲ 0.11 (1.23%)
DFML 43.75 Increased By ▲ 2.06 (4.94%)
DGKC 84.20 Increased By ▲ 0.43 (0.51%)
FCCL 33.05 Increased By ▲ 0.28 (0.85%)
FFBL 78.19 Increased By ▲ 2.72 (3.6%)
FFL 11.50 Increased By ▲ 0.03 (0.26%)
HUBC 110.40 Decreased By ▼ -0.15 (-0.14%)
HUMNL 14.80 Increased By ▲ 0.24 (1.65%)
KEL 5.39 No Change ▼ 0.00 (0%)
KOSM 8.28 Decreased By ▼ -0.12 (-1.43%)
MLCF 39.85 Increased By ▲ 0.06 (0.15%)
NBP 61.10 Increased By ▲ 0.81 (1.34%)
OGDC 200.50 Increased By ▲ 0.84 (0.42%)
PAEL 26.75 Increased By ▲ 0.10 (0.38%)
PIBTL 7.88 Increased By ▲ 0.22 (2.87%)
PPL 160.70 Increased By ▲ 2.78 (1.76%)
PRL 26.53 Decreased By ▼ -0.20 (-0.75%)
PTC 18.55 Increased By ▲ 0.09 (0.49%)
SEARL 82.35 Decreased By ▼ -0.09 (-0.11%)
TELE 8.28 Decreased By ▼ -0.03 (-0.36%)
TOMCL 34.43 Decreased By ▼ -0.08 (-0.23%)
TPLP 9.17 Increased By ▲ 0.11 (1.21%)
TREET 17.24 Decreased By ▼ -0.23 (-1.32%)
TRG 61.24 Decreased By ▼ -0.08 (-0.13%)
UNITY 27.70 Increased By ▲ 0.27 (0.98%)
WTL 1.42 Increased By ▲ 0.04 (2.9%)
BR100 10,481 Increased By 74.5 (0.72%)
BR30 31,806 Increased By 92.4 (0.29%)
KSE100 98,077 Increased By 748.6 (0.77%)
KSE30 30,461 Increased By 268.2 (0.89%)

Novartis Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity. Novartis has said it knew of discrepancies in Zolgensma data it had submitted to the US Food and Drug Administration before it won approval for the world's most expensive medicine in May, but delayed informing regulators until June 28 while it completed an internal investigation.
While the FDA has concluded Zolgensma is safe and effective and should remain on the market, the US drug watchdog raised questions about the timing of Novartis's disclosure. US senators have also demanded the Swiss drugmaker explain why it took so long to inform the agency. Novartis could face possible civil or criminal penalties, the FDA has said. Zolgensma treats spinal muscular atrophy, the leading genetic cause of death in infants.
"We are making a voluntary commitment to notify the FDA within five business days of receipt by our quality (control) organisation of any credible allegation related to data integrity impacting any pending application in the Novartis Group," Narasimhan said at an investor event, adding Novartis will take a similar approach in other jurisdictions.
Novartis said it gave "detailed explanations" on Aug. 23 to the FDA about the company's investigation into the data manipulation, and addressed regulators' questions over why the company waited until late June to make disclosures. The company has said it has "exited" scientists it identified in its data manipulation probe. One of those scientists, Brian Kaspar, through his lawyer, has denied wrongdoing.

Copyright Reuters, 2019

Comments

Comments are closed.